

Press Release

ProStrakan Group plc

FDA Moves Sancuso PDUFA Date to mid-June

Galashiels, Scotland, 23 April, 2008 – ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that it has received notification from the US Food and Drug Administration (FDA) of its decision to postpone the Action Date under the Prescription Drug User Fee Act (PDUFA) for Sancuso® by approximately six weeks from early May to mid-June 2008. Their decision has been taken as a result of the well-publicised resourcing issues currently being experienced by FDA.

Commenting, Dr Wilson Totten, Chief Executive of ProStrakan, said:

“We continue to have open and regular dialogue with FDA as they review the Sancuso NDA and we remain on schedule for Sancuso’s approval at the mid-year and US launch in the second half of this year.”

Further enquiries:

ProStrakan

Dr Wilson Totten, Chief Executive
Paul Garvey, Chief Financial Officer
Callum Spreng, Corporate Comms

Tel: +44 (0) 1896 664000

Financial Dynamics

David Yates/Ben Brewerton

Tel: +44 (0) 20 7831 3113

Trout Group (for US investors)

Gitanjali Jain Ogawa

Tel: +1 (646) 378-2949

Notes to Editors:

ProStrakan

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office and development facilities are situated in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain and other EU countries. **www.prostrakan.com**

Sancuso

Sancuso is ProStrakan's novel, patent protected transdermal patch for the prevention of chemotherapy-induced nausea and vomiting (CINV).